hdm1002

Small moleculeexperimental

Clinical trial activity

11 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
5
Phase 3
3
Phase 4
0

Earliest trial started Jun 30, 2024 (NCT06481085)

Timeline

2020s

  1. Jan 1, 2024

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2024

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2025

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07193459Phase 3Aug 12, 2025Hangzhou Zhongmei
NCT07082114Phase 3Jul 14, 2025Hangzhou Zhongmei
NCT06885021Phase 3Mar 28, 2025Hangzhou Zhongmei
NCT06985615Phase 1Mar 18, 2025Hangzhou Zhongmei
NCT06601517Phase 1Oct 31, 2024Hangzhou Zhongmei
NCT06608329Phase 1Oct 31, 2024Hangzhou Zhongmei
NCT06576401Phase 1Aug 27, 2024Hangzhou Zhongmei
NCT06562088Phase 1Aug 16, 2024Hangzhou Zhongmei
NCT06520540Phase 1Jul 28, 2024Hangzhou Zhongmei, Xiamen University
NCT06500299Phase 2Jul 15, 2024Hangzhou Zhongmei, Xiamen University
NCT06481085Phase 2Jun 30, 2024Hangzhou Zhongmei, People's Liberation Army of China
Showing 11 of 11 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Hangzhou ZhongmeiFor profit111132024
Xiamen UniversityAcademic/Hospital2022024
People's Liberation Army of ChinaGovernment1012024
3 organizations
Page 1 / 1